Novartis Pharmaceuticals Corporation
Adakveo is approved for use people 16 years or older who have sickle cell disease to reduce how often certain episodes happen.
The pharmaceutical agent is a selection blocker indicated to reduce the frequency of vassocclusive crises.
Most common side effects associated with Adakveo include nausea, back pain, joint pain and fever.
Filed Under: Drug Discovery, Drug Discovery and Development, Neurological Disease, Oncology, Orphan Drugs